608 related articles for article (PubMed ID: 21103975)
21. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
[TBL] [Abstract][Full Text] [Related]
22. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.
Jonker JW; Merino G; Musters S; van Herwaarden AE; Bolscher E; Wagenaar E; Mesman E; Dale TC; Schinkel AH
Nat Med; 2005 Feb; 11(2):127-9. PubMed ID: 15685169
[TBL] [Abstract][Full Text] [Related]
23. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Elkind NB; Szentpétery Z; Apáti A; Ozvegy-Laczka C; Várady G; Ujhelly O; Szabó K; Homolya L; Váradi A; Buday L; Kéri G; Német K; Sarkadi B
Cancer Res; 2005 Mar; 65(5):1770-7. PubMed ID: 15753373
[TBL] [Abstract][Full Text] [Related]
24. BCRP/ABCG2 inhibitors: a patent review (2009-present).
Wiese M
Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
[TBL] [Abstract][Full Text] [Related]
25. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
27. Impact of breast cancer resistance protein on cancer treatment outcomes.
Ross DD; Nakanishi T
Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
[TBL] [Abstract][Full Text] [Related]
28. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
29. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
30. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2).
Szafraniec MJ; Szczygieł M; Urbanska K; Fiedor L
Drug Metab Rev; 2014 Nov; 46(4):459-74. PubMed ID: 25036722
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T; Ross DD
Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
[TBL] [Abstract][Full Text] [Related]
32. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
[TBL] [Abstract][Full Text] [Related]
33. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2).
Gradhand U; Kim RB
Drug Metab Rev; 2008; 40(2):317-54. PubMed ID: 18464048
[TBL] [Abstract][Full Text] [Related]
35. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Killeen DP; Li Y; Paxton JW; Birch NP; Scheepens A
Eur J Pharmacol; 2014 Jan; 723():346-52. PubMed ID: 24269959
[TBL] [Abstract][Full Text] [Related]
36. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
Hasanabady MH; Kalalinia F
J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.
Leslie EM; Deeley RG; Cole SP
Toxicol Appl Pharmacol; 2005 May; 204(3):216-37. PubMed ID: 15845415
[TBL] [Abstract][Full Text] [Related]
39. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
Imai Y; Tsukahara S; Asada S; Sugimoto Y
Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
[TBL] [Abstract][Full Text] [Related]
40. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
